Applying New Clinical Data to Practice: CCO Independent Conference of the 2021 Virtual ESMO Annual Meeting *

September 16-21, 2021; Virtual
Review experts’ conference preview commentary, Capsule Summary slidesets, and an expert analysis of key studies from the 2021 Virtual ESMO Congress.

Share

Program Content

Activities

COSMIC-021: mCRPC Cohort
COSMIC-021 Phase I Study: Cabozantinib Plus Atezolizumab in Metastatic Castration-Resistant Prostate Cancer
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: September 21, 2021

Expires: September 20, 2022

DESTINY-Gastric02
DESTINY-Gastric02: Trastuzumab Deruxtecan in Western Patients With HER2+ Advanced Gastric or GEJ Cancer With Progression Following First-line Trastuzumab-Containing Therapy
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: September 22, 2021

Expires: September 21, 2022

DESTINY-Breast03
DESTINY-Breast03: Trastuzumab Deruxtecan vs Trastuzumab Emtansine in Previously Treated HER2+ Metastatic Breast Cancer
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: September 23, 2021

Expires: September 22, 2022

CASPIAN: 3-Yr OS
CASPIAN: 3-Yr Survival Update of First-line Durvalumab + Tremelimumab + EP vs Durvalumab + EP vs EP Alone in Extensive-Stage SCLC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: September 23, 2021

VESPER
VESPER: Phase III Trial of Perioperative Chemotherapy With Dose-Dense MVAC vs Gemcitabine + Cisplatin in Patients With Muscle-Invasive Bladder Cancer
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: September 27, 2021

Expires: September 26, 2022

PEACE-1: OS in mCSPC
PEACE-1: Overall Survival With Abiraterone With or Without Local Radiotherapy + SoC in de novo Metastatic Castration-Sensitive Prostate Cancer
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: September 27, 2021

Expires: September 26, 2022

DESTINY-Lung01: HER2mut Cohort
DESTINY-Lung01: Phase II Trial of Trastuzumab Deruxtecan in HER2-Mutated Metastatic NSCLC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: September 27, 2021

Expires: September 26, 2022

CheckMate 649
CheckMate 649: Updated Results From Phase III Trial of First-line Nivolumab + CT or Ipilimumab vs CT in Advanced Gastroesophageal Cancers
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: September 28, 2021

Expires: September 27, 2022

TULIP
Phase III TULIP: vic-Trastuzumab Duocarmazine vs Physician’s Choice Treatment in Previously Treated HER2+ Advanced Breast Cancer
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: September 28, 2021

Expires: September 27, 2022

KEYNOTE-355 Final Results
KEYNOTE-355: Randomized, Placebo-Controlled Phase III of Pembrolizumab + Chemotherapy in Previously Untreated Metastatic TNBC (Final Results)
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: September 28, 2021

COSMIC-311 Final Analysis
COSMIC-311 Final Analysis: Phase III Trial of Cabozantinib vs Placebo in Radioiodine-Refractory Differentiated Thyroid Cancer After VEGFR TKI
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: September 29, 2021

Expires: September 28, 2022

Abiraterone + ADT in High-Risk M0 PCa
STAMPEDE Combined Analysis of ADT Plus Abiraterone Acetate + Prednisolone ± Enzalutamide vs ADT Alone in High-Risk Nonmetastatic Prostate Cancer
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: September 30, 2021

Expires: September 29, 2022

Dato-DXd in NSCLC With Mutations
Datopotamab Deruxtecan in Advanced NSCLC With Actionable Genomic Alterations: TROPION-Pan Tumor01 Phase I Trial Subset Analysis
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: September 30, 2021

Expires: September 29, 2022

VISION: HRQoL, Pain, Safety
VISION: HRQoL, Pain, and Safety Outcomes With 177Lu-PSMA-617 in Previously Treated Metastatic Castration-Resistant Prostate Cancer
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: September 30, 2021

Expires: September 29, 2022

EPOCH
EPOCH: Phase III Trial Comparing Transarterial Radioembolization With Yttrium-90 + Second-line CT vs CT Only in Patients With Unresectable Colorectal Liver Metastases
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: October 01, 2021

Expires: September 30, 2022

Activities

ESMO 2021: Preview
An Expert’s Guide to ESMO 2021: A Preview of the Top Abstracts
Clinical Thought
Conference Coverage
Congratulations: You achieved a completion on 04/09/2022

Released: September 15, 2021

Expires: September 14, 2022

Faculty

cover img faculity

Eva M. Ciruelos, MD, PhD

Associate Professor
Medicine and Surgery
Complutense University
Medical Oncologist, Breast Cancer Coordinator
Medical Oncology Dpt, Hospital 12 de Octubre and HM Hospitales
Madrid, Spain

cover img faculity

Karim Fizazi, MD, PhD

Full Professor
Cancer Medicine
Gustave Roussey
Villejuif, France

cover img faculity

Eric Van Cutsem, MD, PhD

Head, Digestive Oncology Unit
University Hospital Gasthuisberg
Leuven, Belgium

cover img faculity

Vamsidhar Velcheti, MD

Professor of Medicine
NYU Grossman School of Medicine
Medical Director
Thoracic Oncology Program
Laura and Isaac Perlmutter Cancer Center
An NCI-designated Comprehensive Cancer Center
New York, New York 

Provided by

ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Daiichi Sankyo, Inc.

Exelixis, Inc.

Ipsen Biopharmaceuticals Inc

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.